Browse products

Related products

more on pharma »
more on Central and Eastern Europe »

In vitro diagnostics market in Poland 2010 Development forecasts for 2010-2012

January 2010
Pages: 115
Delivery: PDF


Our clients say... 
“It's a great pleasure to cooperate with PMR because of its analysts' wealth of experience in understanding the local market. We consider PMR a competent and professional company which helps us conduct our business. I would also like to state that PMR's team is always ready to respond to emerging customer needs. We can recommend it as a reliable partner.” Business Analyst, Hilti Distribution, Russia
“Sanofi-Aventis group regularly order PMR's reports and newsletters concerning the Polish pharmaceutical market. We use PMR's services because of the wealth of experience of its analysts in undertaking market analysis and a high level of quality and involvement in the field of market research. ” General Manager, Sanofi-Synthelabo
“PMR reports are a serious contribution to the market overview picture, focusing our attention on key events in the industry as well as highlighting both general and specific market indicators. Together, these components are the base for our future forecasts of construction market development and help us to plan our sales. ” Market Analyst, Alpha Cement
“PMR's analysts understand our needs well and the standard of their service has always fully met our expectations. We are looking forward to cooperating with PMR in the future as well. ” Senior Trade and Investment Adviser, British Embassy in Warsaw
“PMR provides a good service and is always open to discussion. All reports are well structured & are always on time.” Member of the Managment Board, SCA Hygiene Products
“We use PMR's services due to their analysts' extensive experience in market analysis, their high quality and level of engagement in the market research carried out for us. We consider PMR a competent and professional company and recommend them as a reliable partner in the area of economic information and market analysis.” Senior Trade and Investment Adviser, British Embassy in Warsaw
“We consider PMR a competent and professional company. PMR analysts understand our needs clearly and their services have fully met our expectations. I strongly recommend the company as a reliable partner in providing economic information and market analysis.” General Manager, Sanofi-Synthelabo
“As a London-based company, with operations abroad, we looked for the best-in-class Market Intelligence supplier. PMR brought us quality reports that improved our CEE market knowledge and understanding.” Development Manager, GVA Grimley
„Given the fact that Poles will come to spend more on diagnostics, we expect the market to fare well, forecasting an annualized growth rate in the neighbourhood of 10% in the coming years.”

Monika Stefanczyk, Head Pharmaceutical Market Analyst

In vitro diagnostics in Poland 2010 provides a detailed analysis of the in vitro diagnostics market (IVD) in Poland including development forecast up to 2012. It delivers market value and trends visible in the sector. The profiles and market share of the ten largest key multinational players in the IVD market are presented together with the leading Polish companies.

The report presents:
  • overview and market analysis of the diagnostics sector in Poland:
    • clinical chemistry
    • products for diabetics
    • immunology and Immunochemistry
    • hematology, histology and cytology
    • microbiology
    • molecular diagnostics
  • market share and value of the IVD market in Poland
  • market trends and forecasts of the IVD market in Poland
  • company profiles of the leading players in the IVD market in Poland
  • law regulations and anticipated changes
  • epidemiologic and demographic trends
The report has been prepared using PMR MarketInsight Methodology

Request sample pages/interactive screenshare

To receive more information on this report, please sign up.

*required

*Would you like a FREE
interactive screenshare?
*Email:
To make sure you receive the requested information, add info@pmrcorporate.com to your company trusted emails. Contact your IT department for details.
*Your company core business:

Privacy Policy

  1. Report methodology

  2. Executive summary

  3. Overview of the in-vitro diagnostics market in Poland

    • Key events and trends in the in-vitro diagnostics market in 2007-2009
    • Expected trends and developments in 2010-2012
    • The value of the IVD market in 2004-2
    • and the IVD market summary
    • Foreign trade
      • Blood-grouping reagents
      • Opacifying preparations for x-ray examinations; diagnostic reagents for administration to patients

  4. Analysis of individual segments of the IVD market

    • Clinical chemistry
      • Products for diabetics
    • Immunology and immunochemistry
    • Haematology, histology and cytology
    • Microbiology
    • Molecular diagnostics

  5. Key players in the IVD market in Poland

    • Key Polish players in the IVD market
  6. Medical diagnostic laboratories
    • Market overview
    • The number and type of laboratories
    • The location of laboratories
    • Profiles of selected top market players
    • Legal environment

  7. Legal aspects

    • Key legislation
    • The Act on Medical Devices
    • Reimbursement aspect
    • Specialist medical supplies shops

  8. Demographic and epidemiological trends

    • Demographic trends
    • Epidemilogical trends and disease diagnostics
    • Cardiovascular diseases
    • Neoplasms
    • Infectious diseases

  9. List of graphs

  10. List of tables

  11. About PMR

  12. Contact PMR

List of graphs

  1. The value (PLN m) and change of the IVD market in Poland, 2004-2012
  2. Debt due from independent public healthcare centres in Poland (PLN bn), Q1 2005-Q3 2009
  3. Total debt of independent healthcare centres in Poland (PLN bn), Q1 2005-Q3 2009
  4. Frequency of tests for cholesterol, PSA and FOBT in Poland compared to the EU average, 2006
  5. Distribution of spending by healthcare sector in Poland, 2004-2012
  6. The value (PLN bn) and change of the private healthcare market in Poland, 2005-2011
  7. The value (PLN m) and change of the IVD market in Poland, 2004-2012
  8. Imports of blood-grouping reagents (PLN m) to Poland and imports growth, 2004-H1 2009
  9. Imports of blood-grouping reagents to Poland, by country, 2008
  10. Imports of blood-grouping reagents to Poland, by country, H1 2009
  11. Imports of opacifying preparations for x-ray examinations and diagnostic reagents for administration to patients (PLN m) to Poland and imports growth, 2004-H1 2009
  12. Imports of opacifying preparations for x-ray examinations and diagnostic reagents for administration to patients to Poland, by country, 2008
  13. Imports of opacifying preparations for x-ray examinations and diagnostic reagents for administration to patients to Poland, by country, H1 2009
  14. Exports of opacifying preparations for x-ray examinations and diagnostic reagents for administration to patients (PLN m) from Poland and exports growth, 2004-H1 2009
  15. Exports of opacifying preparations for x-ray examinations and diagnostic reagents for administration to patients from Poland, by country, 2008
  16. Exports of opacifying preparations for x-ray examinations and diagnostic reagents for administration to patients from Poland, by country, H1 2009
  17. Shares of the Polish IVD market sectors by value, 2008
  18. Operating segments of the IVD market in Poland by value, 2008
  19. The value (PLN m) and growth of the clinical chemistry segment of the IVD market in Poland, 2005-2008
  20. The value structure of sales of reagents used in clinical chemistry in Poland, 2008
  21. The growth in the value of sales of individual segments of reagents used in clinical chemistry in Poland, 2008
  22. The value (PLN m) and growth of the segment of diabetic tests and products for diabetics of the IVD market in Poland, 2005-2008
  23. The value structure of sales of reagents used in immunochemistry and immunology in Poland, 2008
  24. The value structure of sales of reagents used in infectious immunology in Poland, 2008
  25. The growth in the value of sales of individual segments of reagents used in immunochemistry and immunology in Poland, 2008
  26. The growth in the value of sales of individual segments of reagents used in infectious immunology in Poland, 2008
  27. The value (PLN m) and growth of the immunology and immunochemistry segment of the IVD market in Poland, 2005-2008
  28. The value structure of sales of instruments used in chemistry and immunochemistry and sales growth in Poland, 2008
  29. The value (PLN m) and growth of the haematology, histology and cytology segment of the IVD market in Poland, 2005-2008
  30. The value structure of sales of reagents used in haematology, histology and cytology and sales growth in Poland, 2008
  31. The value structure of sales of instruments used in haematology, histology and cytology and sales growth in Poland, 2008
  32. The value (PLN m) and growth of the microbiology segment of the IVD market in Poland in 2005-2008
  33. The value structure of sales of reagents used in microbiology and sales growth in Poland, 2008
  34. The value (PLN m) and growth of the molecular segment of the IVD market in Poland, 2005-2008
  35. Revenue of Roche Diagnostics (PLN m) and revenue growth in Poland, 2004-2008
  36. Net profit of Roche Diagnostics (PLN m) and net profit change in Poland, 2004-2008
  37. Contribution of the Polish division to global revenue of Roche Diagnostics, 2003-2008
  38. Revenue of Abbott (PLN m) and revenue change in Poland, 2004-2008
  39. Net profit of Abbott (PLN m) and net profit change in Poland, 2004-2007
  40. Revenue of bioMerieux (PLN m) and revenue growth in Poland, 2003-2008
  41. Net profit (PLN m) of bioMerieux and net profit change in Poland, 2003-2008
  42. Sales revenue by type and y-o-y change by business segments of bioMerieux in Poland, 2009
  43. Contribution of the Polish division to global revenue of bioMerieux, 2003-2008
  44. Revenue of Siemens Healthcare Diagnostics (PLN m) and revenue growth in Poland, 2007-2009
  45. Net financial result of Siemens Healthcare Diagnostics (PLN m) in Poland, 2007-2008
  46. Contribution of the Polish division to global revenue of Siemens Healthcare Diagnostics, 2007-2008
  47. Revenue of Johnson & Johnson (PLN m) and revenue growth in Poland, 2004-2007
  48. Revenue of Comesa (PLN m) and revenue growth in Poland, 2004-2008
  49. Net profit of Comesa (PLN m) and net profit growth in Poland, 2004-2008
  50. Revenue of Becton Dickinson (PLN m) and revenue change in Poland, 2003-2008
  51. Net profit of Becton Dickinson (PLN m) and net profit change in Poland, 2003-2008
  52. Revenue of Sysmex (PLN m) and revenue growth in Poland, 2005-2009
  53. Net profit of Sysmex (PLN m) and net profit growth in Poland, 2005-2009
  54. Revenue of Biomedica (PLN m) and revenue growth in Poland, 2004-2008
  55. Net profit (loss) of Biomedica (PLN m) in Poland, 2004-2008
  56. Revenue of Genexo (PLN m) and revenue change in Poland, 2004-2007
  57. Net profit (loss) of Genexo (PLN m) in Poland, 2003-2007
  58. Revenue from domestic sales (PLN m) of PZ Cormay and revenue change, 2004-Q3 2009
  59. Revenue from export sales (PLN m) of PZ Cormay and revenue change, 2004-Q3 2009
  60. Net profit of PZ Cormay (PLN m) and net profit change, 2004-Q3 2009
  61. Sales revenue by type and sales growth by business segments of PZ Cormay, Q1-Q3 2009
  62. Structure of PZ Cormay’s revenue by operating segment, Q1-Q3 2009
  63. Revenue of Hand-Prod (PLN m) and revenue change in Poland, 2005-2006
  64. Revenue of Transfarm (PLN m) and revenue change in Poland, 2003-2008
  65. Net profit of Transfarm (PLN m) and net profit change in Poland, 2003-2008
  66. Revenue of Emapol (PLN m) and revenue change in Poland, 2003-2008
  67. Net profit of Emapol (PLN m) and net profit change in Poland, 2003-2008
  68. Revenue of Bio-Ksel (PLN m) and revenue growth in Poland, 2003-2008
  69. Net profit of Bio-Ksel (PLN m) and net profit change in Poland, 2006-2008
  70. Revenue of Pro Scientium (PLN m) and revenue change in Poland, 2004-2006
  71. Net profit (loss) of Pro Scientium (PLN m) in Poland, 2004-2006
  72. Power configuration (PLN m) on the IVD market in Poland, 2004-2008
  73. Public and non-public healthcare facilities performing laboratory tests in Poland, December 2009
  74. The number of healthcare facilities performing laboratory tests in Poland, by voivodship, December 2009
  75. The number of entities of healthcare facilities performing laboratory tests in Poland, by voivodship, December 2009
  76. The number of entities of healthcare facilities performing laboratory tests in Poland (per 10,000 residents), by voivodship, December 2009
  77. Revenue and net profit of Diagnostyka (PLN m) in Poland, 2003-2007
  78. The location of Diagnostyka’s laboratories in Poland (the number of laboratories), December 2009
  79. Revenue and net profit (PLN m) of Synevo Polska, 2005-2007
  80. The location of Synevo’s laboratories in Poland (the number of laboratories), December 2009
  81. The location of Alpha Medical’s laboratories in Poland (the number of laboratories), December 2009
  82. The location of Medical Laboratories Fryda in Poland (the number of laboratories), December 2009
  83. Poland’s population (million), 2004-2035
  84. Population forecast for selected age groups in Poland (million), 2004-2035
  85. Life expectancy at birth in Poland (years), 1990-2035
  86. Deaths caused by cardiovascular diseases, by type of disease, Poland, 2006

List of tables

  1. Top 10 players on the Polish IVD market, 2007 and 2008
  2. The number of diagnostic laboratories by type in Poland, November 2009
  3. The list of diagnostic tests ordered and financed by primary care doctors, which are required when offering primary healthcare benefits in Poland, 2009
  4. Specialist medical supplies shops in Poland, 2008
In vitro diagnostics market in Poland 2010
Development forecasts for 2010-2012

Choose your version of this product:

Select
language: 		Select
licence: 		     Price: 1700 €
Language / Licence Single 5 Users Corporate Global
English or Polish1700€2550€3400€4250€
English and Polish2380€3570€4760€5950€

Compare licences
  • "Single user licence" entitles the client to use the product (in its entirety or in part, and in the case of an online product also to use the access data to this product) only and exclusively in the following fields of exploitation:
    • - for the product preservation: saving the product in the memory of one computer belonging to the client;
    • - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for the individual use of one person only, who is indicated by the client during purchasing process.

      Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
  • "5-user licence" entitles the client to use the product (in its entirety or in part, and in the case of an online product also to use the access data to this product) only and exclusively in the following fields of exploitation:
    • - for the product preservation: saving the product in the memory of 2 to 5 computers belonging to the organisation indicated by the client while purchasing process; these computers must be located in the same country as the organisation indicated during purchasing process;
    • - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for 2 to 5 people who work for the organisation indicated by the client during purchasing process, and who are in the same country as the organisation indicated during purchasing process.

      Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
  • "Corporate licence" entitles the client to use the product (in its entirety or in part, and in the case of an online product also to use the access data to this product) only and exclusively in the following fields of exploitation:
    • - for the product preservation: saving the product in the memory of an unlimited number of computers belonging to the organisation indicated by the client during purchasing process; these computers must be located in the same country as the organisation indicated during purchasing process;
    • - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for an unlimited number of people who work for the organisation indicated by the client during purchasing process, who are in the same country as the organisation indicated during purchasing process.

      Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
  • "Global licence" entitles the client to use the product (in its entirety or in part, and in the case of an online product also to use the access data to this product) only and exclusively in the following fields of exploitation:
    • - for the product preservation: saving the product in the memory of an unlimited number of computers belonging to the organisation indicated by the client during purchasing process; these computers can be located in or outside of the country of the organisation indicated during purchasing process;
    • - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for an unlimited number of people who work for the organisation indicated by the client during purchasing process, who are in or outside of the country of the organisation indicated during purchasing process.

      Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
    PMR is a member of SIIA's Corporate Content Anti-Piracy Program. Breaking the conditions of our licences will result in a report being sent to SIIA to initiate a piracy investigation and major fees may be imposed by the SIIA as a result. Additionally, for newsletters and online services, it will result in suspension of the subscription with no money refund.